More Positive Phase IIa Data May Have Vertex CF Drug On Registration Path
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
With more positive safety and efficacy data for its disease-modifying cystic fibrosis candidate, VX-770, Vertex said Oct. 20 it plans to work with U.S. and EU regulatory officials to develop a registration program for the oral CF potentiator